DE69218795T2 - Verbindungen,die neurotransmitter freisetzen,um die lernfähigkeit zu erhöhen - Google Patents

Verbindungen,die neurotransmitter freisetzen,um die lernfähigkeit zu erhöhen

Info

Publication number
DE69218795T2
DE69218795T2 DE69218795T DE69218795T DE69218795T2 DE 69218795 T2 DE69218795 T2 DE 69218795T2 DE 69218795 T DE69218795 T DE 69218795T DE 69218795 T DE69218795 T DE 69218795T DE 69218795 T2 DE69218795 T2 DE 69218795T2
Authority
DE
Germany
Prior art keywords
pyridinylmethyl
dihydro
oxo
phenyl
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69218795T
Other languages
German (de)
English (en)
Other versions
DE69218795D1 (de
Inventor
Richard Earl
Matthew Voss
Wendell Wilkerson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
DuPont Merck Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DuPont Merck Pharmaceutical Co filed Critical DuPont Merck Pharmaceutical Co
Publication of DE69218795D1 publication Critical patent/DE69218795D1/de
Application granted granted Critical
Publication of DE69218795T2 publication Critical patent/DE69218795T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/57—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69218795T 1992-01-16 1992-12-30 Verbindungen,die neurotransmitter freisetzen,um die lernfähigkeit zu erhöhen Expired - Fee Related DE69218795T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82157292A 1992-01-16 1992-01-16
PCT/US1992/011292 WO1993014085A1 (en) 1992-01-16 1992-12-30 Novel neurotransmitter releasers useful for cognition enhancement

Publications (2)

Publication Number Publication Date
DE69218795D1 DE69218795D1 (de) 1997-05-07
DE69218795T2 true DE69218795T2 (de) 1997-07-10

Family

ID=25233729

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69218795T Expired - Fee Related DE69218795T2 (de) 1992-01-16 1992-12-30 Verbindungen,die neurotransmitter freisetzen,um die lernfähigkeit zu erhöhen

Country Status (12)

Country Link
US (1) US5414004A (esLanguage)
EP (1) EP0623127B1 (esLanguage)
JP (1) JP2656157B2 (esLanguage)
AU (1) AU3425493A (esLanguage)
CA (1) CA2128233A1 (esLanguage)
DE (1) DE69218795T2 (esLanguage)
ES (1) ES2100523T3 (esLanguage)
IL (1) IL104417A0 (esLanguage)
MX (1) MX9300205A (esLanguage)
TW (1) TW215437B (esLanguage)
WO (1) WO1993014085A1 (esLanguage)
ZA (1) ZA93276B (esLanguage)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW219935B (esLanguage) * 1991-12-25 1994-02-01 Mitsubishi Chemicals Co Ltd
US5594001A (en) * 1993-04-08 1997-01-14 The Dupont Merck Pharmaceutical Company Polycyclic systems, and derivatives thereof, as neurotransmitter release enhancers useful in the treatment of cognitive disorders
AU690906B2 (en) * 1993-04-08 1998-05-07 Du Pont Pharmaceuticals Company Novel polycyclic systems, and derivatives thereof, as neurotransmitter release enhancers useful in the treatment of cognitive disoders
DK0757685T3 (da) * 1994-04-29 2004-10-25 Pfizer Hidtil ukendte, acycliske og cycliske amider som midler til forögelse af frigivelsen af neurotransmitter
US5750528A (en) * 1995-02-01 1998-05-12 The Dupont Merck Pharmaceutical Company Blockade of neuronal m-channels as a therapeutic approach to the treatment of neurological disease
ATE203530T1 (de) * 1996-05-28 2001-08-15 Pfizer Adamantyl substituierte oxindole als pharmazeutische wirkstoffe
JPH11236333A (ja) * 1997-12-30 1999-08-31 Pfizer Prod Inc 抗ガン剤として有用なイミダゾリン−４−オン誘導体
US20040175691A1 (en) * 1998-12-03 2004-09-09 Brown Barry S. Use of the KCNQ2 and KCNQ3 genes for the discovery of agents useful in the treatment of neurological disorders
US6174903B1 (en) 1998-12-28 2001-01-16 Pfizer Inc. Imidazolidin-4-one derivatives useful as anticancer agents
CN112358434B (zh) * 2020-11-18 2025-04-22 湖南理工学院 一种3-(邻氰基苯甲基)吲哚-2-酮类化合物的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5173489A (en) * 1986-04-10 1992-12-22 The Dupont Merck Pharmaceutical Co. α,α-disubstituted aromatics and heteroaromatics as cognition enhancers
US4760083A (en) * 1986-04-10 1988-07-26 E. I. Dupont De Nemours & Company 3,3-disubstituted indolines
ES2110965T3 (es) * 1989-07-25 1998-03-01 Taiho Pharmaceutical Co Ltd Derivado de oxoindol.
US5006537A (en) * 1989-08-02 1991-04-09 Hoechst-Roussel Pharmaceuticals, Inc. 1,3-dihydro-1-(pyridinylamino)-2H-indol-2-ones

Also Published As

Publication number Publication date
US5414004A (en) 1995-05-09
ES2100523T3 (es) 1997-06-16
ZA93276B (en) 1994-07-15
EP0623127B1 (en) 1997-04-02
DE69218795D1 (de) 1997-05-07
AU3425493A (en) 1993-08-03
CA2128233A1 (en) 1993-07-22
TW215437B (esLanguage) 1993-11-01
EP0623127A1 (en) 1994-11-09
IL104417A0 (en) 1993-05-13
WO1993014085A1 (en) 1993-07-22
MX9300205A (es) 1994-07-29
JPH07503005A (ja) 1995-03-30
JP2656157B2 (ja) 1997-09-24

Similar Documents

Publication Publication Date Title
DE69431751T2 (de) Benzylaminochinuclidinen mit ein durch ein heteronom substituiertes alkyl als substanz p antagoniste
DE69919361T2 (de) Pyridyl-ether und -thioether als nikotin-acetylcholin-rezeptorliganden und ihre therapeutische anwendung
DE69333143T2 (de) Substituierte chinuclidine als substanz p antagonisten
DE69811070T2 (de) 9-azabicyclo(3.3.1)non-2-ene und nonanderivate als liganden der nicotinergen rezeptoren
DE69512797T2 (de) Prostaglandin-synthase hemmer
DE69331329T2 (de) Heterocyclische ether-derivate zur verstärkung der cognitiven funktionen
DE3852335T2 (de) N-(Pyridinyl)-1H-indol-1-amine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel.
DE3856340T2 (de) Verfahren zur Herstellung alpha, alpha-disubstituierter Aromaten und Heteroaromaten als wahrnehmungssteigernde Mittel
EP1129074A2 (de) Anthranilsäureamide und deren verwendung als arzneimittel
DE60011895T2 (de) Heterocyclische subtituierte aminoazacyclische verbindungen mit zentraler nervensystemwirkung
DE69533284T2 (de) Neue cyclische und acyclische amide zur erhöhung der neurotransmitter ausschüttung
WO2001085719A9 (de) Ortho substituierte anthranilsäureamide und deren verwendung als arzneimittel
DE69218795T2 (de) Verbindungen,die neurotransmitter freisetzen,um die lernfähigkeit zu erhöhen
KR101185541B1 (ko) 아릴비닐아자시클로알칸 화합물, 그 제조방법, 및 그 용도
DE69326804T2 (de) 1-Aminoacetamidopyrrole und 1-Amino-2-(substituierte)-Pyrrole und ihre Verwendung zur Behandlung von neurodegenerativen Störungen
DE3787657T2 (de) Aminosäure-Derivate.
DE69817214T2 (de) Azaring-ether-derivate und ihre verwendung als nicotinic-ach-rezeptormodulatoren
US5278162A (en) 3,3'-disubstituted-1,3-dihydro-2H-pyrrolo[2,3-b]heterocyclic-2-one useful in the treatment of cognitive disorders of man
DE69231337T2 (de) Disubstituierte polycyclische systeme als wahrnehmungssteigernde mittel
JPH06293761A (ja) スピロ橋かけ型および非橋かけ型複素環式化合物
DE69310904T2 (de) Verbrückte bis-aryl-carbinol-derivate, zusammensetzungen und ihre verwendung
DE69230498T2 (de) 2-Pyrazinylethylamin-Derivate und ihre Verwendung als Arzneimittel.
DE69406678T2 (de) Heterozyclische amine mit zns-wirksamkeit
DE69920516T2 (de) Substituierte oxime und hydrazone als neurokinin antagonisten
DE69311123T2 (de) Cyclische benzylamino-, benzylamido- und benzylimido derivate als antipsychotische wirkstoffe

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: DU PONT PHARMACEUTICALS CO., WILMINGTON, DEL., US

8339 Ceased/non-payment of the annual fee
8327 Change in the person/name/address of the patent owner

Owner name: BRISTOL-MYERS SQUIBB PHARMA CO., PRINCETON, N.J.,